Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Banting Postdoctoral Fellowship Program

Direct Payment

$140,000.00

Efficacy of a Plasmodium falciparum subunit vaccine and correlates of immunity in malaria-naïve adults following vaccination and challenge via controlled human malaria infection.

FY 2023-24

Summary
Efforts to generate an effective vaccine against malaria have been ongoing for more than a century. Towards this goal, the World Health Organization has set a minimum target of 75% vaccine efficacy (VE) for novel vaccine candidates. In 2021, a vaccine candidate developed at the Jenner Institute known as R21/MatrixMTM exceeded that goal with a VE of 80% in a clinical trial conducted in African children. This vaccine candidate has now been approved for use in children in several countries where malaria is endemic. An estimated 50 million people travel to malaria-endemic regions annually, yet an efficacious vaccination regimen in malaria-naïve adults has not been determined. Current strategies for mitigation rely on prophylaxis with antimalarial medications. Prophylaxis regimens are expensive and failure-prone with significant side-effects limiting their prescription in pregnancy, children, and in those with common neuropsychiatric disorders such as depression. Vaccination with R21/MatrixMTM is not only safe in children, but also avoids the side-effects common to antimalarial medications. Furthermore, the R21/MM vaccine is inexpensive ($4 USD/dose) supporting its implementation as a traveller's vaccine if shown to be effective in this population. We will perform a combined safety and efficacy trial of R21/MatrixMTM in healthy malaria-naïve adult volunteers. VE will be assessed by controlled human infection via infectious mosquito bites conducted at Imperial College London. Clinical and immunologic analyses will be performed at the Jenner Institute in Oxford, UK. Significance: We will identify an effective dosing schedule for vaccination of healthy malaria-naïve adults with R21/MatrixMTM. Our results will build towards a vaccine that protects at-risk populations living in non-endemic regions against malaria disease. Additionally, this postdoctoral training will provide me the experience needed to investigate future vaccines in my own independent research program.
Program
Banting Postdoctoral Fellowship Program
Location
United Kingdom
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
491894
Name
Cook Jonathan D
Country
United Kingdom
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Clinical
Prcname2
Banting Postdoctoral Fellowships Program
Projecttitle
Efficacy of a Plasmodium falciparum subunit vaccine and correlates of immunity in malaria-naïve adults following vaccination and challenge via controlled human malaria infection.
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Banting Postdoctoral Fellowship Program
Keyworddelim
Controlled Human Infection Trial; Malaria; Vaccine
Abstract
Efforts to generate an effective vaccine against malaria have been ongoing for more than a century. Towards this goal, the World Health Organization has set a minimum target of 75% vaccine efficacy (VE) for novel vaccine candidates. In 2021, a vaccine candidate developed at the Jenner Institute known as R21/MatrixMTM exceeded that goal with a VE of 80% in a clinical trial conducted in African children. This vaccine candidate has now been approved for use in children in several countries where malaria is endemic. An estimated 50 million people travel to malaria-endemic regions annually, yet an efficacious vaccination regimen in malaria-naïve adults has not been determined. Current strategies for mitigation rely on prophylaxis with antimalarial medications. Prophylaxis regimens are expensive and failure-prone with significant side-effects limiting their prescription in pregnancy, children, and in those with common neuropsychiatric disorders such as depression. Vaccination with R21/MatrixMTM is not only safe in children, but also avoids the side-effects common to antimalarial medications. Furthermore, the R21/MM vaccine is inexpensive ($4 USD/dose) supporting its implementation as a traveller's vaccine if shown to be effective in this population. We will perform a combined safety and efficacy trial of R21/MatrixMTM in healthy malaria-naïve adult volunteers. VE will be assessed by controlled human infection via infectious mosquito bites conducted at Imperial College London. Clinical and immunologic analyses will be performed at the Jenner Institute in Oxford, UK. Significance: We will identify an effective dosing schedule for vaccination of healthy malaria-naïve adults with R21/MatrixMTM. Our results will build towards a vaccine that protects at-risk populations living in non-endemic regions against malaria disease. Additionally, this postdoctoral training will provide me the experience needed to investigate future vaccines in my own independent research program.
Competitiondate
202309
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Cook, Jonathan D
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~
Direct Payment - $140,000 Grant (2023-24) | Canada Spends